Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
NanoLogix Rapid TB Detection Results Published In Journal of Microbial & Biochemical Technology

NanoLogix (OTC Markets: NNLX)

An independent third-party study by one of the foremost Biomedical Research centers in the U.S. has demonstrated that NanoLogix's BioNanoPore (BNP) Ultra-Fast Identification Technology enables detection of live Tuberculosis cultures in five days as opposed to two+ weeks with traditional methods.

The peer reviewed study appears in the online edition of the Journal of Microbial & Biochemical Technology.

http://www.omicsonline.org/1948-5948/pdfdownload.php?download=JMBT-04-147.pdf&&aid=10157

The authors conclude: "Ideally, highly accurate diagnostic tests for TB would be simple to perform, not require specialized equipment or facilities, provide rapid results for decreased time to treatment, are readily available, and cost-effective for the end user. These qualities are especially important in developing or high-TB burdened countries where the access and ability to purchase specialized equipment is limited, and number of trained personnel is low. The results of the present study demonstrate a proof-of-principal for BNP™ Middlebrook in detecting TB compared to the Middlebrook 7H10 reference test and should be considered as an ideal candidate for future evaluation of clinical samples.”

Current rapid detection methods using PCR (molecular diagnostic) technology have a number of limitations in the fight against TB. They are unable to differentiate between live actual infection, and presence of dead bacteria in immune patients. Furthermore, PCR technology is very expensive, and needs specially trained personnel to perform testing, something not available, or even feasible, in the areas of the world most in need. Furthermore, even with PCR, the standard still requires culture positivity, which currently is a 3-4 week process. In addition, drug sensitivity is equally as important as identification, and early results using our BNF technology are extremely encouraging, taking only a few hours after bacterial identification.

Potential for the use of BNP technology is vast, said Bret T. Barnhizer, CEO of NanoLogix. “In addition to BNP’s use in detecting many other bacteria, we see this technology as potentially providing both a standalone method for determining the presence of an actual TB infection and also a complementary method that can be used with either our BioNanoFilter (BNF) technology or molecular diagnostics methods for initial TB screening. We hope that our BNP rapid culture results will make it possible to finally monitor antibiotic treatment for TB in a close-to-real-time manner that is currently unavailable to practitioners. This ability could provide major assistance in the ongoing campaign to combat the scourge of Tuberculosis. We are committed to helping wipe out this horrible disease that takes over one million lives a year. As a partner in the Stop TB Alliance, we look forward to working further with them and WHO officials in a real effort to eradicate TB.”

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing. Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity. For more information visit: www.nanologix.com.

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

About Business Wire
Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
Compute virtualization has been transformational, yet security policy implementation and enforcement has lagged behind in agility and automation. There are a number of key considerations when implementing policy in private and hybrid clouds. In his session at 15th Cloud Expo, H...
SYS-CON Events announced today that SOA Software, an API management leader, will exhibit at SYS-CON's 15th International Cloud Expo®, which will take place on November 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA. SOA Software is a leading provider of API M...
How do APIs and IoT relate? The answer is not as simple as merely adding an API on top of a dumb device, but rather about understanding the architectural patterns for implementing an IoT fabric. There are typically two or three trends: Exposing the device to a management framewo...
SYS-CON Events announced today that Utimaco will exhibit at SYS-CON's 15th International Cloud Expo®, which will take place on November 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA. Utimaco is a leading manufacturer of hardware based security solutions that...
Samsung VP Jacopo Lenzi, who headed the company's recent SmartThings acquisition under the auspices of Samsung's Open Innovaction Center (OIC), answered a few questions we had about the deal. This interview was in conjunction with our interview with SmartThings CEO Alex Hawkinson...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE

Breaking Cloud Computing News

SAN JOSE, Calif., Oct. 23, 2014 /PRNewswire/ -- Altera Corporation (NASDAQ: ALTR) today announced...